AbbVie Long Term Debt 2010-2024 | ABBV

AbbVie long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
  • AbbVie long term debt for the quarter ending March 31, 2024 was $63.805B, a 7.61% increase year-over-year.
  • AbbVie long term debt for 2023 was $52.194B, a 11.74% decline from 2022.
  • AbbVie long term debt for 2022 was $59.135B, a 7.87% decline from 2021.
  • AbbVie long term debt for 2021 was $64.189B, a 17.23% decline from 2020.
AbbVie Annual Long Term Debt
(Millions of US $)
2023 $52,194
2022 $59,135
2021 $64,189
2020 $77,554
2019 $62,975
2018 $35,002
2017 $30,953
2016 $36,440
2015 $29,240
2014 $10,538
2013 $14,292
2012 $14,630
2011 $32
2010 $
2009 $
AbbVie Quarterly Long Term Debt
(Millions of US $)
2024-03-31 $63,805
2023-12-31 $52,194
2023-09-30 $55,631
2023-06-30 $55,812
2023-03-31 $59,292
2022-12-31 $59,135
2022-09-30 $60,399
2022-06-30 $61,002
2022-03-31 $63,522
2021-12-31 $64,189
2021-09-30 $74,049
2021-06-30 $74,237
2021-03-31 $74,183
2020-12-31 $77,554
2020-09-30 $82,282
2020-06-30 $82,061
2020-03-31 $63,284
2019-12-31 $62,975
2019-09-30 $33,126
2019-06-30 $31,619
2019-03-31 $35,066
2018-12-31 $35,002
2018-09-30 $36,487
2018-06-30 $30,579
2018-03-31 $30,906
2017-12-31 $30,953
2017-09-30 $33,974
2017-06-30 $33,817
2017-03-31 $36,526
2016-12-31 $36,440
2016-09-30 $37,284
2016-06-30 $37,328
2016-03-31 $29,490
2015-12-31 $29,240
2015-09-30 $31,359
2015-06-30 $27,116
2015-03-31 $10,683
2014-12-31 $10,538
2014-09-30 $14,469
2014-06-30 $14,470
2014-03-31 $14,386
2013-12-31 $14,292
2013-09-30 $14,375
2013-06-30 $14,326
2013-03-31 $14,601
2012-12-31 $14,630
2012-09-30
2012-06-30
2012-03-31
2011-12-31 $32
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $279.466B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $768.355B 111.05
Novo Nordisk (NVO) Denmark $608.375B 46.75
Johnson & Johnson (JNJ) United States $360.280B 14.31
Merck (MRK) United States $332.026B 60.41
AstraZeneca (AZN) United Kingdom $242.395B 21.07
Novartis AG (NVS) Switzerland $206.669B 14.65
Pfizer (PFE) United States $162.575B 20.20
Sanofi (SNY) $123.959B 11.69
Innoviva (INVA) United States $0.986B 6.93